Computed tomography assessment of lung density in patients with lung cancer treated with accelerated hypofractionated radio-chemotherapy supported with amifostine

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 3, 2009, Pages 258-261

  Koukourakis, Michael I ^a   Tsoutsou, Pelagia G ^a   Abatzoglou, Ioannis ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Amifostine; Lung fibrosis; Radiotherapy

Indexed keywords

AMIFOSTINE; DOXORUBICIN; NAVELBINE; NAVELIBINE; OXALIPLATIN; TROPISETRON; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DENSITY; DIAGNOSTIC VALUE; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; LUNG; LUNG FIBROSIS; LUNG INJURY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG VOLUME; MALE; NAUSEA; PATIENT COMPLIANCE; PNEUMONIA; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AMIFOSTINE; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PULMONARY FIBROSIS; RADIATION INJURIES; RADIOTHERAPY, HIGH-ENERGY; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 67749106523     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181845557     Document Type: Article

References (19)

1. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330-353.
2. Sura S, Yorke E, Jackson A, et al. High-dose radiotherapy for the treatment of inoperable non-small cell lung cancer. Cancer J. 2007;13:238-242.
3. Belderbos JS, Heemsbergen WD, De Jaeger K, et al. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:126-134.
4. Chen M, Hayman JA, Ten Haken RK, et al. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation? Int J Radiat Oncol Biol Phys. 2006;64:120-126.
5. Bradley J. A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group. Semin Oncol. 2005; 32:S111-S113.
6. Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs. 2002;13:181-209.
7. Antonadou D, Throuvalas N, Petridis A, et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;57: 402-408.
8. Antonadou D, Coliarakis N, Synodinou M, et al. Clinical Radiation Oncololgy Hellenic Group. Randomized phase III trial of radiation treatment +/ -amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:915-922.
9. Komaki R, Lee JS, Milas L, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004;58:1369-1377.
10. Movsas B, Scott C, Langer C, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol. 2005;23:2145-2154.
11. Komaki R. What should the optimal timing be for amifostine administration relative to radiation and chemotherapy? J Clin Oncol. 2005;23:7232-7233.
12. Cassatt DR, Fazenbaker CA, Kifle G, et al. Effects of dose and schedule on the efficacy of ethyol: preclinical studies. Semin Oncol. 2003;30:S31-S39.
13. Koukourakis MI, Abatzoglou I, Sivridis L, et al. Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy. Anticancer Res. 2006;26:2437-2443.
14. Koukourakis MI, Patlakas G, Froudarakis ME, et al. Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma. Anticancer Res. 2007;27:3625-3631.
15. Tsoutsou P, Froudarakis M, Bouros D. Hypofractionated/ accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC). Anticancer Res. 2008;28:1349-1354.
16. Tsoutsou PG, Koukourakis MI. Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys. 2006;66:1281-1293.
17. López Rodríguez M, Cerezo Padellano L. Toxicity associated to radiotherapy treatment in lung cancer patients. Clin Transl Oncol. 2007;9:506-512.
18. Gopal R. Pulmonary toxicity associated with the treatment of non-small cell lung cancer and the effects of cytoprotective strategies. Semin Oncol. 2005; 32:S55-S59.
19. Reckzeh B, Merte H, Pflüger KH, et al. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol. 1996;14:1071-1076.